Does functional imaging distinguish nodular lymphocyte-predominant hodgkin lymphoma from T-cell/histiocyte-rich large B-cell lymphoma?

Nicholas A. Barber, Fausto R. Loberiza, Anamarija M. Perry, Martin Bast, Karen P. Holdeman, Aliriza B. Esfahane, Dennis D. Weisenburger, Julie Marie Vose, Philip Jay Bierman, James Olen Armitage, Robert G Bociek

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is often associated with concurrent or subsequent development of T-cell/histiocyte-rich large B-cell lymphoma (THR-LBCL). Distinguishing the two is important because their therapies are different. Functional imaging with PET/CT is used to stage both Hodgkin and non-Hodgkin lymphomas. Aggressive lymphomas are usually more PET avid than the indolent subtypes. Therefore, it is possible that PET/CT may help distinguish NLPHL from THR-LBCL. Patients and Methods: Herein, we retrospectively describe the clinical and PET/CT findings of 12 patients with NLPHL or THR-LBCL seen from 2004-2010. Results and Conclusions: Six patients each were identified and the average SUVmax was 6.9 (range, 5.7-7.3) in NLPHL and 16.6 (range, 4-29) in THR-LBCL (p = 0.055). Bone and extranodal involvement was found in one patient with NLPHL compared to four patients with THR-LBCL. This patient failed to respond to ABVD and was subsequently found to have THR-LBCL. We suggest that patients with NLPHL and THR-LBCL have different clinical and PET/CT characteristics. NLPHL patients had lower SUVmax on PET/CT compared to those with THR-LBCL. The presence of bone or extranodal involvement is more common in patients with THR-LBCL. Patients with NLPHL and an uncharacteristically higher SUVmax on PET/CT, or those with bone or extranodal involvement, should alert the clinician to consider the presence of THR-LBCL.

Original languageEnglish (US)
Pages (from-to)392-397
Number of pages6
JournalClinical Lymphoma, Myeloma and Leukemia
Volume13
Issue number4
DOIs
StatePublished - Aug 2013

Fingerprint

Histiocytes
B-Cell Lymphoma
Hodgkin Disease
T-Lymphocytes
Bone and Bones
Non-Hodgkin's Lymphoma
Lymphoma

Keywords

  • Nodular lymphocyte-predominant Hodgkin lymphoma
  • PET/CT
  • T-cell/histiocyte- rich large B-cell lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Does functional imaging distinguish nodular lymphocyte-predominant hodgkin lymphoma from T-cell/histiocyte-rich large B-cell lymphoma? / Barber, Nicholas A.; Loberiza, Fausto R.; Perry, Anamarija M.; Bast, Martin; Holdeman, Karen P.; Esfahane, Aliriza B.; Weisenburger, Dennis D.; Vose, Julie Marie; Bierman, Philip Jay; Armitage, James Olen; Bociek, Robert G.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 13, No. 4, 08.2013, p. 392-397.

Research output: Contribution to journalArticle

Barber, Nicholas A. ; Loberiza, Fausto R. ; Perry, Anamarija M. ; Bast, Martin ; Holdeman, Karen P. ; Esfahane, Aliriza B. ; Weisenburger, Dennis D. ; Vose, Julie Marie ; Bierman, Philip Jay ; Armitage, James Olen ; Bociek, Robert G. / Does functional imaging distinguish nodular lymphocyte-predominant hodgkin lymphoma from T-cell/histiocyte-rich large B-cell lymphoma?. In: Clinical Lymphoma, Myeloma and Leukemia. 2013 ; Vol. 13, No. 4. pp. 392-397.
@article{87930bd396084e3bbb231fb9523ad08a,
title = "Does functional imaging distinguish nodular lymphocyte-predominant hodgkin lymphoma from T-cell/histiocyte-rich large B-cell lymphoma?",
abstract = "Background: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is often associated with concurrent or subsequent development of T-cell/histiocyte-rich large B-cell lymphoma (THR-LBCL). Distinguishing the two is important because their therapies are different. Functional imaging with PET/CT is used to stage both Hodgkin and non-Hodgkin lymphomas. Aggressive lymphomas are usually more PET avid than the indolent subtypes. Therefore, it is possible that PET/CT may help distinguish NLPHL from THR-LBCL. Patients and Methods: Herein, we retrospectively describe the clinical and PET/CT findings of 12 patients with NLPHL or THR-LBCL seen from 2004-2010. Results and Conclusions: Six patients each were identified and the average SUVmax was 6.9 (range, 5.7-7.3) in NLPHL and 16.6 (range, 4-29) in THR-LBCL (p = 0.055). Bone and extranodal involvement was found in one patient with NLPHL compared to four patients with THR-LBCL. This patient failed to respond to ABVD and was subsequently found to have THR-LBCL. We suggest that patients with NLPHL and THR-LBCL have different clinical and PET/CT characteristics. NLPHL patients had lower SUVmax on PET/CT compared to those with THR-LBCL. The presence of bone or extranodal involvement is more common in patients with THR-LBCL. Patients with NLPHL and an uncharacteristically higher SUVmax on PET/CT, or those with bone or extranodal involvement, should alert the clinician to consider the presence of THR-LBCL.",
keywords = "Nodular lymphocyte-predominant Hodgkin lymphoma, PET/CT, T-cell/histiocyte- rich large B-cell lymphoma",
author = "Barber, {Nicholas A.} and Loberiza, {Fausto R.} and Perry, {Anamarija M.} and Martin Bast and Holdeman, {Karen P.} and Esfahane, {Aliriza B.} and Weisenburger, {Dennis D.} and Vose, {Julie Marie} and Bierman, {Philip Jay} and Armitage, {James Olen} and Bociek, {Robert G}",
year = "2013",
month = "8",
doi = "10.1016/j.clml.2013.03.004",
language = "English (US)",
volume = "13",
pages = "392--397",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "4",

}

TY - JOUR

T1 - Does functional imaging distinguish nodular lymphocyte-predominant hodgkin lymphoma from T-cell/histiocyte-rich large B-cell lymphoma?

AU - Barber, Nicholas A.

AU - Loberiza, Fausto R.

AU - Perry, Anamarija M.

AU - Bast, Martin

AU - Holdeman, Karen P.

AU - Esfahane, Aliriza B.

AU - Weisenburger, Dennis D.

AU - Vose, Julie Marie

AU - Bierman, Philip Jay

AU - Armitage, James Olen

AU - Bociek, Robert G

PY - 2013/8

Y1 - 2013/8

N2 - Background: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is often associated with concurrent or subsequent development of T-cell/histiocyte-rich large B-cell lymphoma (THR-LBCL). Distinguishing the two is important because their therapies are different. Functional imaging with PET/CT is used to stage both Hodgkin and non-Hodgkin lymphomas. Aggressive lymphomas are usually more PET avid than the indolent subtypes. Therefore, it is possible that PET/CT may help distinguish NLPHL from THR-LBCL. Patients and Methods: Herein, we retrospectively describe the clinical and PET/CT findings of 12 patients with NLPHL or THR-LBCL seen from 2004-2010. Results and Conclusions: Six patients each were identified and the average SUVmax was 6.9 (range, 5.7-7.3) in NLPHL and 16.6 (range, 4-29) in THR-LBCL (p = 0.055). Bone and extranodal involvement was found in one patient with NLPHL compared to four patients with THR-LBCL. This patient failed to respond to ABVD and was subsequently found to have THR-LBCL. We suggest that patients with NLPHL and THR-LBCL have different clinical and PET/CT characteristics. NLPHL patients had lower SUVmax on PET/CT compared to those with THR-LBCL. The presence of bone or extranodal involvement is more common in patients with THR-LBCL. Patients with NLPHL and an uncharacteristically higher SUVmax on PET/CT, or those with bone or extranodal involvement, should alert the clinician to consider the presence of THR-LBCL.

AB - Background: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is often associated with concurrent or subsequent development of T-cell/histiocyte-rich large B-cell lymphoma (THR-LBCL). Distinguishing the two is important because their therapies are different. Functional imaging with PET/CT is used to stage both Hodgkin and non-Hodgkin lymphomas. Aggressive lymphomas are usually more PET avid than the indolent subtypes. Therefore, it is possible that PET/CT may help distinguish NLPHL from THR-LBCL. Patients and Methods: Herein, we retrospectively describe the clinical and PET/CT findings of 12 patients with NLPHL or THR-LBCL seen from 2004-2010. Results and Conclusions: Six patients each were identified and the average SUVmax was 6.9 (range, 5.7-7.3) in NLPHL and 16.6 (range, 4-29) in THR-LBCL (p = 0.055). Bone and extranodal involvement was found in one patient with NLPHL compared to four patients with THR-LBCL. This patient failed to respond to ABVD and was subsequently found to have THR-LBCL. We suggest that patients with NLPHL and THR-LBCL have different clinical and PET/CT characteristics. NLPHL patients had lower SUVmax on PET/CT compared to those with THR-LBCL. The presence of bone or extranodal involvement is more common in patients with THR-LBCL. Patients with NLPHL and an uncharacteristically higher SUVmax on PET/CT, or those with bone or extranodal involvement, should alert the clinician to consider the presence of THR-LBCL.

KW - Nodular lymphocyte-predominant Hodgkin lymphoma

KW - PET/CT

KW - T-cell/histiocyte- rich large B-cell lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84880750528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880750528&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2013.03.004

DO - 10.1016/j.clml.2013.03.004

M3 - Article

C2 - 23773450

AN - SCOPUS:84880750528

VL - 13

SP - 392

EP - 397

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 4

ER -